Guardant Health, Pfizer Collaborate To Develop New Cancer Therapies Using Liquid Biopsy Platform
Guardant Health, Inc. (NASDAQ:GH) on Thursday announced a strategic collaboration with Pfizer, Inc. (NYSE:PFE) to support the development and commercialization of Pfizer's oncology portfolio using the Guardant Infinity smart liquid biopsy platform.
Under the multi-year collaboration agreement, Guardant and Pfizer aim to:
Utilize Guardant's portfolio of liquid biopsy tests in Pfizer's global clinical studies.
Evaluate the clinical utility of (a) circulating tumor DNA (ctDNA) level as a surrogate endpoint to monitor therapy response and (b) related blood-based epigenomic analyses.
Also Read:
The collaboration will also allow Pfizer to access Guardant's liquid biopsy tests in China for its global clinical trials, which include China cohorts.
In July 2022, Guardant announced a strategic partnership with Adicon Holdings Limited, an independent clinical laboratory company based in China, to offer Guardant tests to biopharmaceutical companies conducting clinical trials in China.
In January, Guardant Health announced that Palmetto GBA, a Medicare administrative contractor that administers the Molecular Diagnostics Services program (MolDX), granted coverage for the Guardant Reveal test to monitor for disease recurrence in patients with colorectal cancer (CRC) following curative intent therapy.
Guardant Reveal, which runs on Guardant's Smart Liquid Biopsy platform, is a blood test that uses epigenomic (methylation) analysis to detect circulating tumor DNA (ctDNA), a marker of minimal residual disease (MRD). This test predicts cancer recurrence, helping to guide clinical decisions after surgery or chemotherapy.
Price Action: GH stock is up 2.59% at $46.82 at the last check Thursday.
Read Next:Photo by Aunt Spray via Shutterstock
Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market.
Get the latest stock analysis from Benzinga?
PFIZER (PFE): Free Stock Analysis Report
This article Guardant Health, Pfizer Collaborate To Develop New Cancer Therapies Using Liquid Biopsy Platform originally appeared on Benzinga.com
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
Why AI Stock Broadcom Topped the Market on Tuesday
It announced that it started shipping its latest AI chip. The chip is a vast improvement over its predecessor, the company said. Meanwhile, two analysts published bullish updates on the stock. These 10 stocks could mint the next wave of millionaires › A new product rollout is always an attention-grabbing piece of news in the corporate world, and that goes double for businesses involved with artificial intelligence (AI). On Tuesday, specialty chip maker Broadcom (NASDAQ: AVGO) announced it began shipping an advanced networking chip. Investors greeted this by pushing the company's stock up by more than 3% that trading session. That gain easily trounced the 0.6% increase of the S&P 500 index. Broadcom's Tomahawk 6 switch series is now on its way to the market, the company announced that morning (a switch, also known as a switching chip, is a highly specialized component that handles data trafficking through a computer network). According to Broadcom, the Tomahawk 6 boasts double the bandwidth of any switch available on the market just now. It's designed to handle the comparably much higher resource needs of artificial intelligence (AI) functionalities. The company said its new product has an unrivaled set of AI routing features and interconnect options. The announcement came two days before Broadcom is slated to publish its fiscal second quarter of 2025 earnings. What also helped the stock rise was a pair of bullish new analyst notes released in anticipation of those results. Both Citigroup's Christopher Danley and JPMorgan Chase's Harlan Sur maintained their equivalent of buy recommendations in their respective updates. Danley went as far as to raise his price target on the stock significantly to $276 per share from his previous $210. According to reports, Danley believes Broadcom will top analyst estimates for the quarter, especially considering that AI is an important driver of its sales, and demand for the technology remains scorching. I'd be as bullish as those two gentlemen; Broadcom is very well placed to be a main supplier expanding AI capabilities, and its fundamentals should reflect that going forward. Ever feel like you missed the boat in buying the most successful stocks? Then you'll want to hear this. On rare occasions, our expert team of analysts issues a 'Double Down' stock recommendation for companies that they think are about to pop. If you're worried you've already missed your chance to invest, now is the best time to buy before it's too late. And the numbers speak for themselves: Nvidia: if you invested $1,000 when we doubled down in 2009, you'd have $356,261!* Apple: if you invested $1,000 when we doubled down in 2008, you'd have $38,291!* Netflix: if you invested $1,000 when we doubled down in 2004, you'd have $657,385!* Right now, we're issuing 'Double Down' alerts for three incredible companies, available when you join , and there may not be another chance like this anytime soon.*Stock Advisor returns as of June 2, 2025 JPMorgan Chase is an advertising partner of Motley Fool Money. Citigroup is an advertising partner of Motley Fool Money. Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends JPMorgan Chase. The Motley Fool recommends Broadcom. The Motley Fool has a disclosure policy. Why AI Stock Broadcom Topped the Market on Tuesday was originally published by The Motley Fool
Yahoo
35 minutes ago
- Yahoo
Jim Cramer on Arrowhead Pharmaceuticals (ARWR): 'It Doesn't Make Any Money'
We recently published a list of . In this article, we are going to take a look at where Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) stands against other stocks that Jim Cramer discusses. When a caller inquired about Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), Cramer said: 'You know, look, it doesn't make any money. I've been waiting for it to do something, break out. I just don't know if it has the horses.' A scientist in a lab coat analyzing a Petri dish surrounded by scientific equipment in a research lab. Arrowhead Pharmaceuticals (NASDAQ:ARWR) develops RNA-based treatments for a wide range of hard-to-treat diseases, with multiple drug candidates in clinical trials targeting conditions such as cardiovascular disorders, liver disease, pulmonary illness, and rare genetic disorders. Additionally, in 2019, Cramer said the following about the company: 'I looked at Arrowhead recently and I didn't see that much. You know, everyone's so excited about it. I don't get that. I have been saying that it's absolutely O.K. to own stocks that have to do with slicing and dicing and genes, but I'm not gonna endorse it for anything other than speculation.' For context, since the above comment was aired, Arrowhead Pharmaceuticals (NASDAQ:ARWR) stock declined more than 75%. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
38 minutes ago
- Yahoo
Procter & Gamble plans to slash 7,000 non-manufacturing jobs over next 2 years
-- Procter & Gamble (NYSE:PG) plans to cut around 7,000 jobs, or roughly 15% of its global non-manufacturing workforce, over the next two years. The move is part of a broader organizational overhaul aimed at simplifying structures by forming smaller teams with expanded responsibilities. The company emphasized that the layoffs are not a cost-cutting measure. The consumer goods maker, known for brands like Tide, Pampers and Bounty, had about 108,000 employees as of last June. Executives announced the restructuring plans during a presentation in Paris, where they also signaled an intention to streamline the company's product portfolio. While specific details were not provided, the changes could involve exiting certain categories and shedding smaller brands in select markets. In April, P&G reported a decline in quarterly sales and lowered its full-year revenue outlook, citing global economic uncertainty and geopolitical instability. The company posted earnings per share (EPS) of $1.54 for the third quarter of fiscal 2025, slightly above the $1.53 that analysts expected. Revenue came in at $19.78 billion, falling short of the $20.11 billion forecast. It also said it was exploring ways to manage the impact of tariffs, including raising prices, reformulating products and tightening costs. Chief Financial Officer Andre Schulten said current tariffs are expected to reduce annual growth by $1 billion to $1.5 billion. To offset the impact, the company plans to rely on pricing, productivity, and innovation in the near term, while also exploring changes in product formulation and sourcing. With one quarter remaining in its fiscal year, P&G currently anticipates flat sales growth for fiscal 2025, a downgrade from its previous projection of 2% to 4%. It also lowered its core earnings outlook to a range of $6.72 to $6.82 per share, down from the earlier forecast of $6.91 to $7.05. Related articles Procter & Gamble plans to slash 7,000 non-manufacturing jobs over next 2 years Citigroup to cut 3,500 jobs at China tech centers BofA sees 62% surge in eVTOL adoption, fueling 'low-altitude' boom Sign in to access your portfolio
